Genomic effects of tamoxifen

Anticancer Research

Volumn 16, Issue 6 B, 1996, Pages 3537-3541

  Kellen, John A ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Antiestrogens; Bcl 2; c myc; erb B2 multidrug resistance; Growth factors; p53; Tamoxifen

Indexed keywords

ANTIESTROGEN; GROWTH FACTOR; MYC PROTEIN; ONCOPROTEIN; PROTEIN BCL 2; PROTEIN ERB B2; PROTEIN P53; TAMOXIFEN; UNCLASSIFIED DRUG;

APOPTOSIS; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; GENE CONTROL; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; MULTIGENE FAMILY; PRIORITY JOURNAL; REVIEW;

ANTINEOPLASTIC AGENTS, HORMONAL; APOPTOSIS; ESTROGEN ANTAGONISTS; GROWTH SUBSTANCES; MEMBRANE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; PROTO-ONCOGENE PROTEINS C-MYC; RECEPTOR, ERBB-2; TAMOXIFEN; TRANSCRIPTION, GENETIC; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0030485496     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (52)

1. Smith JR, Ning Y and Pereira-Smith OM: Why are transformed cells immortal? Is the process reversible? Am J Clin Nutr 55: 1215S-1221S, 1992.
2. Steller H: Mechanisms and Genes of Cellular Suicide. Science 267: 1445-1462, 1995.
3. Damsky CH and Werb Z: Signal transduction by integrin receptors for extracellular matrix: cooperative processing of extracellular information. Curr Opin Cell Biol 4: 772-781, 1992.
4. Hynes RO: Integrins: versatility, modulation and signalling in cell adhesion. Cell 69: 11-255, 1992.
5. Lonn U, Lonn S, Nilsson B and Stenkvist B: Intratumoraal heterogeneity for amplified genes in human breast carcinoma. Int J Cancer 58: 40-45, 1994.
6. Arao Y, Yamamoto E, Miyatake N, Ninomyia Y, Umehara T, Kawashima H, Masushige S, Hasegawa T and Kato S: A synthetic oestrogen antagonist, tamoxifen, inhibits oestrogen-induced transcriptional. but not post-transcriptional. regulation of gene expression. Biochem J 313: 269-274, 1996.
7. Murphy LJ and Murphy LC: Regulation of growth factor gene expression by Tamoxifen. In: Tamoxifen: beyond the Antiestrogen (Kellen JA, edit.), Birkhaeuser, Boston 1996.
8. Waakeling AE: Tissue-specific actions of antioestrogens. Mut Res 333: 45-49,1995.
9. Brunner N, Yee D, Kern FG, Dpang-Thomsen M, Lippman ME and Cullen KJ: Effect of endocrine therapy on growth of T61 human breast cancer xenografts is directly correlated to a specific down regulation of insulin-like growth factor II (IGF II). Eur J Cancer 29: 562-569, 1943.
10. Hana V and Murnhy LJ: Expression of insulin-like growth factors and their binding proteins in the estrogen-responsive Ishikawa human endometrial cancer cell line. Endocrinol 135: 2511-2526, 1994.
11. Ignar-Trowbidge D, Teeng C, ROSS K, Parker M, Korach K and McLachlan J: Peptide growth factors elicit estrogen receptordependent transcription of EGF. Mol Endocrinol 7: 992-993, 1993.
12. Gong Y, Ballejo G, Murphy LC and Murphy LJ: Differential effects of estrogen and antiestrogen on transforming growth factor gene expression in endometrial adenocarcinoma cells. Cancer Res 52: 1704-1710, 1992.
13. Gong Y, Murphy LC and Murphy LJ: Hormonal regulation of proliferation and transforming growth factor gene expression in human endometrial adenocarcinoma xenograft. J Steroid Biochem 50: 13-19, 1994.
14. Bates SE, Davidson NE, Valverius EM, Freter CE, Dickson RB, Ram JP, Kudlow JE, Lippman ME and Salomon DS: Expression of transforming growth factor alpha and its messenger ribonucleic acid in human breast cancer: its regulation by estrogen and its possible functional significance. Mol Endocrinol 2: 543-555, 1988.
15. Kang Y, Cortina R and Perry RR: Role of c-myc in Tamoxifen Induced Apoptosis in Estrogen-Independent Breast Cancer Cells. JNCI 88: 279-284, 1996.
16. Chen HM, Tritton TR, Kenny N, Absher M and Chiu JF: Tamoxifen induces TGF-betal activity and apoptosis of human MCF-7 breast cancer cells in vitro. J Cell Biochem 61: 9, 1996.
17. Kang Y and Perry RR: Role of c-myc in tamoxifen-induced apoptosis in MDA-231 human breast cancer cells. Proc Amer Assoc Cancer Res 36: 10, 1995.
18. Warri AM and Harkonen PL: Antiestrogen regulation of erb-B2 expression in human breast cancer cells. In: Tamoxifen: beyond the Antiestrogen (Kellen JA,edit.) Birkhaeuser Boston, 1996.
19. Ciocca DR, Fujimura FK, Tandon AK, Clark GM, Mark C, Lee-Chen GJ, Pounds GW, Vendely P, Owens MA, Pandian MR and McGuire WL: Correlation of HER2/neu amplification with expression and with other prognostic factors in 1103 breast cancers. JNCI 84: 1279-1282, 1992.
20. Wàrri AM, Laine AM, Majasuo KE, Alitalo KK and Hàrkónen PL: Estrogen suppression of erb-B2 expression is associated with increased growth rate of ZR-75-1 human breast cancer cells in vitro in nude mice. Int J Cancer 49: 616-623, 1991.
21. Taverna D, Antiniotti S, Maggiora P, Dati C, De Bortoli M and Hynes NE: erb-B2 expression in estrogen receptor-positive breast tumor cells is regulated by growth-modulatory reagents. Int J Cancer 56: 522-528, 1994.
22. Borg A, Baldetorp B, Fernó M, Killander D, Olsson H and Sigurdsson H: erb-B2 amplification in breast cancer with a high rate of proliferation. Oncogene 6: 137-143, 1991.
23. Borg A, Baldetorp B, Fernó M, Killander D, Olsson H, Ryden S and Sigurdsson H: erb-B2 amplification is associated with tamoxifen resistance in steroid receptor-positive breast cancer. Cancer Lett 81: 137-144, 1994.
24. Johnston SRD, Salter J, MacLennan KA, Sacks NM, McKinna JA, Smith IE and Dowsett M: Short-term Tamoxifen induces the cytoplasmic expression of c-erbB2 and bcl-2 in ER-positive human primary breast cancer. The Breast 1: 166, 1992.
25. Vargas-Roig LM, Lotfi H, Olcese JE, Lo-Castro G and Ciocca DR: Effects of Short-Term Tamoxifen Administration in Patients with Invasive Cervical Carcinoma. Anticancer Res 13: 2457-2464, 1993.
26. Harlozinska A and Bar JK: Relationship between p53 and c-erbB2 Overexpression in Tissue Sections and Cyst Fluid Cells of Patients with Ovarian Cancer. Tumor Biol 15: 223-229, 1994.
27. Gelmann EP: Tamoxifen Induction of Apoptosis in Estrogen Receptor-Negative Cancers: New Tricks for an Old Dog? JNCI 88: 224-226, 1996.
28. Teixeira C, Reed JC and Pratt MA: Estrogen promotes chemotherapeutic drug resistance by a mechanism involving bcl-2 protooncogene expression in human breast cancer cells. Cancer Res 55: 3902-3907, 1955.
29. Lu Q-L, Abel P, Foster CS and Lalani E-N: bcl-2: Role in Epithelial Differentiation and Oncogenesis. Hum Pathol 27: 102-110, 1996.
30. Frankfurt OS, Sugarbaker EV, Robb J and Villa L: Apoptosis in breast cancer cells induced by tamoxifen and calmodulin inhibitors. Proc Amer Assoc Cancer Res 36: 44, 1995.
31. Horvath G: Estradiol influences p53 expression in a dosedependent manner in human endometrial adenocarcinomas grown in nude mice. Abstr. #22, in: 5th Internat Conf Anticancer Res (Corfu, Greece) p. 1633, 1996.
32. Rotter V, Foord O and Navot N: In search of the functions of normal p53. Trends Cell Biol 3: 46-49, 1993.
33. Stewart BW: Mechanisms of Apoptosis: Integration of Genetic. Biochemical and Cellular Indicators. JNCI 86: 1286-1296, 1994.
34. Skopelitou A, Kamina S, Hadjiyannakis M, Alexopoulo V, Kirkoni O and Agnatis NJ: Immunohistochemical evaluation of p53. c-myc and bcl-2 expression in hepatocellular carcinoma: correlation with clinicopathological data. Conference Abstr., Tumor Markers: From Biology to Therapy. Oct. 1995 (Athens, Greece).
35. Wyllie A: In: Cell Death in Cancer and Development tMeeting Report), Cancer Res 54: 2812, 1994.
36. Lohman D, Ruhri Ch, Graeff H and Hoefler H: Die Wertigkeit des immunohistochemischen Nachweises von p53 in Mammakarzinomen als Indikator des P53 Gens. Verb Dtsch Ges Pathol 76: 279, 1992.
37. Kellen JA: Differential Regulation of Steroid Receptors, P-Glycoprotein and p53 Protein by Tamoxifen. J Endocr Invest 17 (Suppl 1 to No.3): 75, 1994.
38. Kellen JA: Multidrug Resistance. In: Reversal of Multidrug Resistance (Kellen JA, edit.) CRC Press, Boca Raton 1994.
39. Fine RL, Sachs CW, Safa A, Albers MA, Burchette J and Rao US: Inhibition of MDR by tamoxifen: mechanisms of action. Proc Amer Asooc Cancer Res 34: A1935, 1993.
40. Germann UA and Harding MW: Chemosensitizers to Overcome and Prevent Multidrug Resistance ? JNCI 87: 1573-1575, 1995.
41. Kirk J, Syed SK, Harris AL, Jarman M, Roufogalis BD, Stratford IJ and Carmichael J: Reversal of P-glycoprotein-mediated multidrug resistance by pure anti-oestrogens and novel tamoxifen derivatives. Biochem Pharmacol 48: 277-285, 1994.
42. Lonn U, Lonn S and Stenkvist B: Appearance of amplification of mdr-1 in stage IV breast cancer patients receiving endocrine treatment. 4th Internatl Congr Anticancer Chemotherapy (Paris, France 1993).
43. Altuvia S, Stein WD, Goldenberg S, Kane SE, Pastan I and Gottesman MM: Targeted Disruption of the Mouse mdr1b Gene Reveals That Steroid Hormones Enhance mdr Expression. J Biol Chem 268: 27127-27132, 1993.
44. Arango H, Satyaswaroop P, Cavanagh D, Goldfain V and Becker J: Effects of 17beta-estradiol and mifepristone (RU486) on p-glycoprotein in the Ishikawa human endometrial cancer cell line. Proc Amer Assoc Cancer Res 37: 327, 1996.
45. Vickers PJ, Dickson RB, Shoemaker R and Cowan KH: A multidrugresistant MCF-7 human breast cancer cell line which exhibits cross-resistance to antiestrogens and hormone-independent tumor growth in vivo. Mol Endocrinol 2: 886-892, 1988.
46. Plouzek CA and Yeh GC: Hormonal regulation of P-glycoprotein expression in rat placental cells and rat tissues. Proc Amer Soc Cancer Res. 36: 414, 1995.
47. Kellen JA, George E and Ling V: Decreased P-glycoprotein in an Tamoxifen-Tolerant Breast Carcinoma Model. Anticancer Res 11: 1243-1244, 1991.
48. Kellen JA, Wong ACH and Mirakian A: Immunohistochemical Determination of P-Glycoprotein in a Rat Mammary Tumour Treated with Tamoxifen. in vivo 6: 541-544, 1992.
49. Kellen JA (edit.) Alternative Mechanisms of Multidrug Resistance in Cancer. Birkhaeuser Boston, 1995.
50. McClelland RA, Gee JMW, Dixon A and Blamey RW: Patient stratification for tamoxifen therapy based on cell biology. Internatl Conf Long-term Antihormonal Therapy for Breast Cancer (Lake Buena Vista, FL, UsSA, 1991).
51. Ramkumar T and Adler S: Differential Positive and Negative Transcriptional Regulation by Tamoxifen. Endocrinology 136: 536-542, 1995.
52. Rochefort H: Oestrogen- and anti-oestrogen-regulated genes in human breast cancer. In: Non-Reproductive Actions of Sex Steroids.CIBA Found Symp vol 191, p.254. John Wiley & Sons (Chichester) 1995.